STOCK TITAN

Haemonetics Corp. - HAE STOCK NEWS

Welcome to our dedicated news page for Haemonetics (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Haemonetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Haemonetics's position in the market.

Rhea-AI Summary
Haemonetics (HAE) to release Q4 and fiscal year 2024 financial results on May 9, 2024, followed by an investor conference call. Webcast available for replay for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
-
Rhea-AI Summary
Haemonetics receives FDA clearance for TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge, expanding testing capabilities for heparinized patients in cardiovascular and liver surgeries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
-
Rhea-AI Summary
Haemonetics completes acquisition of Attune Medical, a manufacturer of esophageal cooling device, with an upfront cash payment of $160 million. The acquisition is expected to contribute $30-35 million in revenue in fiscal year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
Rhea-AI Summary
Haemonetics Corporation (NYSE: HAE) announces acquisition of Attune Medical, a manufacturer of ensoETM esophageal cooling device, for $160 million upfront with additional contingent consideration. The deal aims to enhance Haemonetics' presence in the electrophysiology market and improve patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
-
Rhea-AI Summary
Haemonetics Corporation's President and CEO, Chris Simon, will participate in a fireside chat with investors at the Raymond James 45th Annual Institutional Investors Conference on March 5, 2024. The event will be live webcasted and a replay will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
conferences
-
Rhea-AI Summary
Haemonetics Corporation's President and CEO, Chris Simon, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day. The webcast will be available for public access, with a replay option for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
conferences
Rhea-AI Summary
Haemonetics Corporation (HAE) has released its financial results for the third quarter of fiscal year 2024, ending on December 30, 2023. The company will host a conference call and webcast to discuss the results with investors and analysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
-
Rhea-AI Summary
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2024 financial results on February 8, 2024, at 6:00 am ET, followed by a conference call at 8:00 am ET to discuss the results and answer questions. Investors and analysts can access the call via teleconference or live webcast on the company's investor relations website. A replay of the call will be available for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
-
Rhea-AI Summary
Haemonetics Corporation (NYSE: HAE) completes acquisition of OpSens Inc., a medical device cardiology-focused company, for approximately USD $255 million, expanding its Hospital portfolio with innovative fiber optic sensor technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
Rhea-AI Summary
Haemonetics Corporation (NYSE: HAE) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
Haemonetics Corp.

NYSE:HAE

HAE Rankings

HAE Stock Data

4.33B
50.37M
0.76%
101.04%
4.01%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Boston

About HAE

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right